CA2116633A1 - Methode de diagnostic de la migraine familiale hemiplegique (fhm) - Google Patents

Methode de diagnostic de la migraine familiale hemiplegique (fhm)

Info

Publication number
CA2116633A1
CA2116633A1 CA002116633A CA2116633A CA2116633A1 CA 2116633 A1 CA2116633 A1 CA 2116633A1 CA 002116633 A CA002116633 A CA 002116633A CA 2116633 A CA2116633 A CA 2116633A CA 2116633 A1 CA2116633 A1 CA 2116633A1
Authority
CA
Canada
Prior art keywords
polymorphisms
fhm
dna
microsatellites
family
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002116633A
Other languages
English (en)
Inventor
Anne Marie Gisele Joutel
Nee Bousser Marie-Germaine Madeleine Jeanne Van Effenterre
Elisabeth Andree Tournier-Lasserve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to CA002116633A priority Critical patent/CA2116633A1/fr
Publication of CA2116633A1 publication Critical patent/CA2116633A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002116633A 1994-02-28 1994-02-28 Methode de diagnostic de la migraine familiale hemiplegique (fhm) Abandoned CA2116633A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002116633A CA2116633A1 (fr) 1994-02-28 1994-02-28 Methode de diagnostic de la migraine familiale hemiplegique (fhm)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002116633A CA2116633A1 (fr) 1994-02-28 1994-02-28 Methode de diagnostic de la migraine familiale hemiplegique (fhm)

Publications (1)

Publication Number Publication Date
CA2116633A1 true CA2116633A1 (fr) 1995-08-29

Family

ID=4152989

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002116633A Abandoned CA2116633A1 (fr) 1994-02-28 1994-02-28 Methode de diagnostic de la migraine familiale hemiplegique (fhm)

Country Status (1)

Country Link
CA (1) CA2116633A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055647A1 (fr) * 1997-06-06 1998-12-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methode de diagnostic genotypique indirect de la migraine hemiplegique familiale de type 2

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055647A1 (fr) * 1997-06-06 1998-12-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methode de diagnostic genotypique indirect de la migraine hemiplegique familiale de type 2
FR2764306A1 (fr) * 1997-06-06 1998-12-11 Inst Nat Sante Rech Med Methode de diagnostic genotypique indirect de la migraine hemiplegique familiale de type 2

Similar Documents

Publication Publication Date Title
US5714319A (en) Method for the screening of familial hemiplegic migraine (FHM)
Bolos et al. Population and pedigree studies reveal a lack of association between the dopamine D2 receptor gene and alcoholism
Tournier-Lasserve et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12
Joutel et al. A gene for familial hemiplegic migraine maps to chromosome 19
Fischbeck et al. X‐linked neuropathy: gene localization with DNA probes
US6162604A (en) Methods for determining genetic predisposition to autoimmune diseases by genotyping apoptotic genes
Ranum et al. Localization of the autosomal dominant HLA-linked spinocerebellar ataxia (SCA1) locus, in two kindreds, within an 8-cM subregion of chromosome 6p.
Saker et al. High prevalence of a missense mutation of the glucokinase gene in gestational diabetic patients due to a founder-effect in a local population
Farrer et al. Locus heterogeneity for Waardenburg syndrome is predictive of clinical subtypes
EP0672172B1 (fr) Detection de mutations du syndrome de digeorge
Giunti et al. The trinucleotide repeat expansion on chromosome 6p (SCA1) in autosomal dominant cerebellar ataxias
US8206911B2 (en) Identification of the gene and mutation responsible for progressive rod-cone degeneration in dog and a method for testing same
US5942392A (en) Genetic markers used jointly for the diagnosis of Alzheimer's disease, and diagnostic method and kit
Whaley et al. Mapping of D4S98/S114/S113 confines the Huntington's defect to a reduced physical region at the telomere of chromosome 4
Stevanin et al. The gene for spinal cerebellar ataxia 3 (SCA3) is located in a region of approximately 3 cM on chromosome 14q24. 3-q32. 2.
US6660477B2 (en) Method for the determination of data for the preparation of the diagnosis of phakomatosis
AU693562B2 (en) Method and probes for detecting markers bound to the locus of child spinal muscular atrophies
EP0827550B1 (fr) Procede permettant de diagnostiquer l'hemochromatose hereditaire
Detera-Wadleigh et al. Neuropeptide gene polymorphisms in affective disorder and schizophrenia
US5616462A (en) Method for the diagnosis of CADASIL
CA2116633A1 (fr) Methode de diagnostic de la migraine familiale hemiplegique (fhm)
Binczak-Kuleta et al. DNA microsatellite analysis in families with autosomal dominant polycystic kidney disease (ADPKD): the first Polish study
EP0275298B1 (fr) Sondes dmd
Çabuk et al. TBX1 gene mutation screening in patients with non-syndromic Fallot tetralogy
EP0780478A1 (fr) Procédé pour le diagnostique indirect de CADASIL

Legal Events

Date Code Title Description
FZDE Discontinued